Last update 22 May 2025

Allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (ΔLNGFR) and the herpes simplex I virus thymidine kinase (HSV-TK Mut2)

Overview

Basic Info

Drug Type
T-lymphocyte cell therapy
Synonyms
allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (ΔLNGFR) and the herpes simplex I virus thymidine kinase (HSV-TK Mut2), Herpes simplex virus thymidine kinase (HSV-Tk) donor lymphocytes, HSV-Tk
+ [5]
Target-
Action
stimulants
Mechanism
Cell replacements, Immunostimulants
Active Indication-
Originator Organization
Active Organization-
Inactive Organization
Drug Highest PhaseWithdrawn
First Approval Date
Regulation-
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hematologic Neoplasms
European Union
18 Aug 2016
Hematologic Neoplasms
Iceland
18 Aug 2016
Hematologic Neoplasms
Liechtenstein
18 Aug 2016
Hematologic Neoplasms
Norway
18 Aug 2016
Hematopoietic stem cell transplantation
European Union
18 Aug 2016
Hematopoietic stem cell transplantation
Iceland
18 Aug 2016
Hematopoietic stem cell transplantation
Liechtenstein
18 Aug 2016
Hematopoietic stem cell transplantation
Norway
18 Aug 2016
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acute Lymphoblastic LeukemiaPhase 2
Germany
01 Jul 2002
Acute Lymphoblastic LeukemiaPhase 2
Greece
01 Jul 2002
Acute Lymphoblastic LeukemiaPhase 2
Israel
01 Jul 2002
Acute Lymphoblastic LeukemiaPhase 2
Italy
01 Jul 2002
Acute Lymphoblastic LeukemiaPhase 2
United Kingdom
01 Jul 2002
Acute Myeloid LeukemiaPhase 2
Germany
01 Jul 2002
Acute Myeloid LeukemiaPhase 2
Greece
01 Jul 2002
Acute Myeloid LeukemiaPhase 2
Israel
01 Jul 2002
Acute Myeloid LeukemiaPhase 2
Italy
01 Jul 2002
Acute Myeloid LeukemiaPhase 2
United Kingdom
01 Jul 2002
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
-
TK-DLI
dfgymgqoqq(teiryhzcxf) = wbilmdnzhy fevmuowxft (fhcubfxomv )
-
20 Jun 2006
Not Applicable
8
Tk-DLI
tyqwechnjh(urfqgpnxdj) = Multiple doses of ganciclovir (10 mg/kg/die), in the absence of immunosuppressive drugs, quickly resulted in the complete resolution of all signs of GvHD weycujrnhu (zbaavreyyg )
-
15 Jul 2004
Not Applicable
8
cxuigoxtyq(qtpqkfmolo) = 1/8 patients experienced grade II biopsy-proven acute GvHD, involving the skin and the liver. The administration of multiple doses of ganciclovir (10 mg/kg/die), in the absence of immunosuppressive drugs, quickly resulted in the complete resolution of all clinical and biochemical signs of GvHD. Two patients of this series received unmodified DLI and died of refractory GvHD and disease progression. muyhkjfpos (rxwpaqzrls )
Positive
01 May 2002
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free